profits compared to our forecast. The reason is found in still subdued royalty
fees from Arista in the US, otherwise the business is performing according to
our expectations. The focus for 2022 is primarily on the launch of new
products from the company’s proprietary technology platform, known as DSM
products since they are based on so-called degradable starch microspheres. We
expect sales of these products to accelerate during the year. For now, we keep
our valuation interval unchanged at SEK 46.60 – 62.80 per share.
Aktuellt
SENASTE
